EUVIMEDEUVIMED entdecken
Multizentrische Studie

Trajectories and Prognostic Significance of 6-Minute Walk Test Parameters in Fibrotic Interstitial Lung Disease

Yet H Khor, Malik Farooqi, Nathan Hambly, Kerri A Johannson, Veronica Marcoux, Jolene H Fisher, Deborah Assayag, Helene Manganas, Nasreen Khalil, Martin Kolb, Christopher J Ryerson, Austin ILD Registry and CARE-PF Investigators

CHEST · 2023-02 · 163 (2) · 345-357

DOI: 10.1016/j.chest.2022.08.2233 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift CHEST, 2023-02. Verfasst von Yet H Khor und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Research@Alfred, Central Clinical School, Monash University, Melbourne, VIC, Australia; Department of Respiratory and Sleep…. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Idiopathic Pulmonary Fibrosis. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Boehringer Ingelheim Corp USA, NHMRC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Functional capacity, as measured by the 6-min walk test (6MWT), is often reduced in fibrotic interstitial lung disease (ILD). This study evaluated longitudinal changes and the prognostic significance of 6MWT parameters, and explored change in oxygenation status as a physiological criterion to define disease progression in patients with fibrotic ILD. RESEARCH QUESTIONS: What are the trajectories and prognostic value of 6MWT parameters in patients with fibrotic ILD? STUDY DESIGN AND METHODS: Using prospective registries in Australia and Canada, patients with idiopathic pulmonary fibrosis (IPF) and non-IPF fibrotic ILD were stratified by the presence of criteria for progressive pulmonary fibrosis (PPF). The cumulative incidence of exertional and resting hypoxemia and changes in 6-min walk distance (6MWD) and composite indices (distance-saturation product and distance-saturation-oxygen product) were determined, with prognostic significance evaluated at the time of meeting criteria for PPF. New-onset exertional or resting hypoxemia was evaluated as another potential criterion for PPF. RESULTS: Patients with IPF/PPF (n = 126) and non-IPF/PPF (n = 227) had a similar cumulative incidence of exertional hypoxemia and annualized decline in 6MWD and composite indices, which varied across each PPF criterion. Patients with IPF/non-PPF (n = 231) and non-IPF/non-PPF (n = 531) had a significantly lower incidence of hypoxemia than those with IPF/PPF, with an annualized increase in 6MWD and composite indices in the non-IPF/non-PPF group. Exertional or resting hypoxemia at the time of meeting criteria for PPF was independently associated with reduced transplant-free survival in IPF and non-IPF, adjusting for patient demographics and lung function. Adding new-onset exertional or resting hypoxemia as a physiological criterion reduced the median time to development of PPF from 11.2 to 6.7 months in IPF and from 11.7 to 5.6 months in non-IPF in patients who eventually met both definitions (P < .001 for both). INTERPRETATION: Patients with IPF/PPF and non-IPF/PPF have comparable deterioration in functional capacity. Oxygenation status provides prognostic information in PPF and may assist in defining disease progression in fibrotic ILD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung Diseases, InterstitialIdiopathic Pulmonary FibrosisHumansPrognosisWalk TestProspective StudiesDisease ProgressionHypoxia

Stichwörter der Autor:innen

6-min walk testhypoxemiaidiopathic pulmonary fibrosisinterstitial lung diseaseprogressive pulmonary fibrosis

Autor:innen und Institutionen

  • Department of Respiratory Research@Alfred, Central Clinical School, Monash University, Melbourne, VIC, Australia; Department of Respiratory and Sleep Medicine, Austin Health, Heidelberg, VIC, Australia; Institute for Br…
  • Department of Medicine, Firestone Institute for Respiratory Health, McMaster University, Hamilton, ON, Canada.
  • Department of Medicine, University of Calgary, Calgary, AB, Canada.
  • Department of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.
  • Department of Medicine, University of Toronto, Toronto, ON, Canada.
  • Department of Medicine, McGill University, Montreal, QC, Canada.

Förderung

  • Boehringer Ingelheim Corp USA
  • NHMRC

Zitieren

APA

Khor, Y. H., Farooqi, M., Hambly, N., Johannson, K. A., Marcoux, V., Fisher, J. H., Assayag, D., Manganas, H., Khalil, N., Kolb, M., Ryerson, C. J., & Austin ILD Registry and CARE-PF Investigators (2023). Trajectories and Prognostic Significance of 6-Minute Walk Test Parameters in Fibrotic Interstitial Lung Disease. CHEST, 163(2), 345-357. https://doi.org/10.1016/j.chest.2022.08.2233

Vancouver

Khor YH, Farooqi M, Hambly N, Johannson KA, Marcoux V, Fisher JH, et al. Trajectories and Prognostic Significance of 6-Minute Walk Test Parameters in Fibrotic Interstitial Lung Disease. CHEST. 2023;163(2):345-357. doi:10.1016/j.chest.2022.08.2233

BibTeX
@article{Khor2023,
  author = {Khor, Yet H and Farooqi, Malik and Hambly, Nathan and Johannson, Kerri A and Marcoux, Veronica and Fisher, Jolene H and Assayag, Deborah and Manganas, Helene and Khalil, Nasreen and Kolb, Martin and Ryerson, Christopher J and Austin ILD Registry and CARE-PF Investigators, Austin ILD Registry and CARE-PF Investigators},
  title = {Trajectories and Prognostic Significance of 6-Minute Walk Test Parameters in Fibrotic Interstitial Lung Disease},
  journal = {CHEST},
  year = {2023},
  volume = {163},
  number = {2},
  pages = {345--357},
  doi = {10.1016/j.chest.2022.08.2233}
}
Kostenlos starten →